Molecular diagnostics in esophageal and gastric neoplasms

Muhammad Zulfiqar, Amarpreet Bhalla, Michael Weindel, Vinod B. Shidham

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.

Original languageEnglish (US)
Pages (from-to)867-873
Number of pages7
JournalClinics in Laboratory Medicine
Volume33
Issue number4
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Molecular Pathology
Esophageal Neoplasms
Epidermal Growth Factor
Stomach Neoplasms
Carcinoma
Tumors
Stomach
Esophagogastric Junction
Neoplasms
Barrett Esophagus
Cause of Death
Survival
Incidence

Keywords

  • Adenocarcinoma
  • Esophagus
  • Gastric carcinoma
  • HER-2
  • Molecular genetics
  • Squamous cell carcinoma
  • Trastuzumab

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Molecular diagnostics in esophageal and gastric neoplasms. / Zulfiqar, Muhammad; Bhalla, Amarpreet; Weindel, Michael; Shidham, Vinod B.

In: Clinics in Laboratory Medicine, Vol. 33, No. 4, 01.12.2013, p. 867-873.

Research output: Contribution to journalReview article

Zulfiqar, Muhammad ; Bhalla, Amarpreet ; Weindel, Michael ; Shidham, Vinod B. / Molecular diagnostics in esophageal and gastric neoplasms. In: Clinics in Laboratory Medicine. 2013 ; Vol. 33, No. 4. pp. 867-873.
@article{41891f8308c34e8591f81331caad6fd3,
title = "Molecular diagnostics in esophageal and gastric neoplasms",
abstract = "Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.",
keywords = "Adenocarcinoma, Esophagus, Gastric carcinoma, HER-2, Molecular genetics, Squamous cell carcinoma, Trastuzumab",
author = "Muhammad Zulfiqar and Amarpreet Bhalla and Michael Weindel and Shidham, {Vinod B.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.cll.2013.08.006",
language = "English (US)",
volume = "33",
pages = "867--873",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Molecular diagnostics in esophageal and gastric neoplasms

AU - Zulfiqar, Muhammad

AU - Bhalla, Amarpreet

AU - Weindel, Michael

AU - Shidham, Vinod B.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.

AB - Esophageal carcinoma is the most rapidly increasing tumor in incidence in the United States. It has an established association with a precursor lesion (Barrett esophagus). Gastric carcinoma (GC) is the second leading cause of cancer death in the world. The prognosis for patients with advanced stage GC and esophageal carcinoma is poor. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset of GC. HER-2 overexpressing tumors are eligible for HER-2 targeted therapies, which lead to a better survival in these patients.

KW - Adenocarcinoma

KW - Esophagus

KW - Gastric carcinoma

KW - HER-2

KW - Molecular genetics

KW - Squamous cell carcinoma

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84888203978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888203978&partnerID=8YFLogxK

U2 - 10.1016/j.cll.2013.08.006

DO - 10.1016/j.cll.2013.08.006

M3 - Review article

C2 - 24267191

AN - SCOPUS:84888203978

VL - 33

SP - 867

EP - 873

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 4

ER -